Alamar Biosciences develops NULISA™ technology, which enables the detection of protein biomarkers from a single liquid biopsy sample with attomolar sensitivity and a dynamic range of up to 12 logs. This technology addresses the challenge of early disease diagnosis by providing researchers with a high-throughput platform for profiling clinically relevant biomarkers across various diseases, including cancer and neurodegenerative disorders.
Funding
$308M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ASFounders
Product
Problem
Current protein analysis technologies often fail to detect a significant portion of the human plasma proteome, hindering early disease diagnosis and personalized medicine. Clinically relevant biomarkers require ultra-high sensitivity to enable earlier disease detection.
Solution
Alamar Biosciences provides proteomics solutions that empower researchers to deeply interrogate the proteome with high-throughput precision. The company's NULISA technology enables accurate detection of highly multiplexed protein biomarkers from small liquid biopsy specimens, achieving attomolar sensitivity and a dynamic range of up to 12 logs. This technology reduces background noise inherent in multiplex assays, expediting the discovery, profiling, and validation of clinically relevant, translatable protein biomarkers across the therapeutic development pipeline. Alamar Biosciences also offers the ARGO HT System, which automates the proteomics workflow.
Target Audience
The primary customers are researchers from academic institutions, core labs, biopharmaceutical companies, and biotech companies who are focused on biomarker discovery, translational proteomics, and advancing precision medicine.
Features
- NULISA technology with attomolar sensitivity and up to 12-log dynamic range
- NULISA assays for immunology, neurology, and oncology
- NULISAseq CNS Disease Panel 120 with blood-based brain-derived pTau assays
- NULISAseq Mouse Panel 120 for preclinical research
- NULISAqpcr Custom Assay Development Kit for novel biomarker assays
- ARGO HT System for automated proteomics workflow
- Alamar Analysis Solutions for data analysis
- Technology Access Program (TAP)